Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06243614 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase Ⅲ Clinical Trial of Buagafuran Capsules in the Treatment of GAD

Study acronym: BGFN-2022-01
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 6, 2024 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A placebo-controlled superiority design was used to evaluate the efficacy of 60-120 mg/ day of Buagafuran capsules in the treatment of GAD.
Trial Details
NCT Number NCT06243614
Lead Sponsor Beijing Union Pharmaceutical Factory Ltd
Collaborators: R&G Pharma Studies Co.,Ltd.
Conditions Generalized Anxiety Disorder
Enrollment 410 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov